comparemela.com
  1. Home
  2. Live Updates
  3. Saadz Usmani - Breaking News

Latest Breaking News On - Saadz usmani - Page 1 : comparemela.com

Revisit Every OncLive On Air Episode From April 2024

Revisit Every OncLive On Air Episode From April 2024
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkNew havenYale universityLos angelesRhode islandCity ofUnited kingdomMemorial sloan kettering cancer centerBrown universityElias bou farhatSarah rutherfordIan rabinowitzSaadz usmaniMatthew lunningBou farhar

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

Saadz usmaniMemorial sloan kettering cancer centerMyeloma serviceMemorial sloan kettering cancer centerOnclive tvMultiple myeloma

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

New yorkUnited statesSaadz usmaniOncologic drugs advisory committeeJanssen biotech incMeeting of the oncologic drugs advisory committeeDrugs advisory committeeMyeloma serviceMemorial sloan kettering cancer center

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

New yorkUnited statesSaadz usmaniChris ryanLive on airMyeloma serviceMemorial sloan kettering cancer centerOnclive on airApple podcastsGoogle podcastsAmazon musicFda approval of cilta celPatients with relapsed refractory multiple myeloma

Dr Usmani on the Optimal Role for Cilta-Cel in Relapsed/Refractory Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the optimal role for ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Saadz usmaniMemorial sloan kettering cancer centerMyeloma serviceFda approval of cilta celRelapsed refractory multiple myeloma

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.